

11:45 a.m. – 1:00 p.m. Lunch (on your own)

1:00 p.m. – 2:20 p.m. Session 3: *Integration of Nuclear Receptors and Homeostasis*
Moderator: Chris Glass, University of California (UC) at San Diego

1:00 p.m. *Nuclear Receptors and the Metabolic Syndrome*
Mitch Lazar, University of Pennsylvania

1:20 p.m. *Nuclear Receptors, Inflammation, and Metabolic Disease*
Chris Glass, UC at San Diego

1:40 p.m. *Metabolic Control Through the PGC-1/SIRT1 Transcriptional Complex Activity*
Pere Puigserver, Dana Farber Cancer Institute

2:00 p.m. *Discussion*

2:20 p.m. – 2:40 p.m. Break

2:40 p.m. – 3:10 p.m. Clinical/Translational Challenges: Overview
Saul Karpen, Baylor College of Medicine

3:10 p.m. – 4:50 p.m. Session 4: *Hepatic Pathophysiology of Nuclear Receptors*
Moderator: Michael Trauner, Medical University of Graz

3:10 p.m. *Molecular Regulation of Hepatic Fibrosis and the Role of Nuclear Receptors*
Scott Friedman, Mount Sinai School of Medicine

3:30 p.m. *Nuclear Receptors and Hepatotoxicity*
Wen Xie, University of Pittsburgh Medical College

3:50 p.m. *Cholestasis*
Michael Trauner, Medical University of Graz

4:10 p.m. *Late-Breaking Story:
Identification of Heme as the Ligand for the Orphan Nuclear Receptors Rev-Erba and
Rev-Erb β*
Thomas Burris, Pennington Biomedical Research Center

4:30 p.m. *Discussion*

5:00 p.m. – 7:00 p.m. Poster Session

Day 2—Thursday, November 8, 2007

8:00 a.m. – 9:40 a.m. Session 5: *Disease States and Nuclear Receptors*
Moderator: Joel Lavine, UC at San Diego

8:00 a.m. *Isolated Genetic Defects in Nuclear Receptors*
Krishna Chatterjee, Cambridge University

8:20 a.m. *Nuclear Receptors and Inflammatory Bowel Disease*
Frank Gonzalez, National Cancer Institute

8:40 a.m. *Non-Alcoholic Steatohepatitis*
Joel Lavine, UC at San Diego

- 9:00 a.m. *Gallstones*
Alan Hofmann, UC at San Diego
- 9:20 a.m. *Discussion*
- 9:40 a.m. – 10:00 a.m. Break**
- 10:00 a.m. – 10:45 a.m. Session 6: *Late-Breaking Stories***
Moderator: Ronald Margolis, NIDDK
- 10:00 a.m. *Decreased Histone H3K9 Acetylation at Bile Acid Transporter Gene Promoters During Rat Liver Development and Obstructive Cholestasis*
Meena Ananthanarayanan, Mount Sinai Medical Center
- 10:15 a.m. *Farnesoid X Receptor, the Bile Acid Activated Nuclear Receptor, Attenuates Colon Cancer Development in Mice*
Grace Guo, University of Kansas Medical Center
- 10:30 a.m. *A Randomized, Placebo-controlled Trial of the PPAR γ Ligand Rosiglitazone for Active Ulcerative Colitis*
Gary Wu, University of Pennsylvania
- 10:45 a.m. – 12:45 p.m. Session 7: *Translation***
Moderator: Erin Schuetz, St. Jude's Hospital for Children
- 10:45 a.m. *Pharmacogenomics*
Erin Schuetz, St. Jude's Hospital for Children
- 11:05 a.m. *The Design and Development of PPARdelta Ligands for the Treatment of Metabolic Syndrome*
Rich Heyman, Kalypsys, Inc.
- 11:25 a.m. *Diabetes, Drug Metabolism, and Vice Versa*
David Moore, Baylor College of Medicine
- 11:55 a.m. *Nuclear Receptors and NASH: Bench to Bedside*
Anna Mae Diehl, Duke University
- 12:15 p.m. *Discussion*
- 12:45 p.m. – 1:00 p.m. Open Discussion: *Meeting Summary and Future Directions***
Panel: Meeting Organizers
- 1:00 p.m. Adjourn**